Boston Scientific to acquire Apollo Endosurgery for more than $600M

Boston Scientific (NYSE:BSX) today announced it entered a definitive agreement to acquire Apollo Endosurgery (NSDQ:APEN) for more than $600 million.

The Marlborough, Massachusetts-based company will acquire the endoluminal surgical device maker for a cash price of $10 per share to reflect an enterprise value of approximately $615 million.

Apollo Endosurgery’s product portfolio includes devices used during endoluminal surgery (ELS) procedures to close gastrointestinal defects, manage gastrointestinal complications and aid in weight loss. ELS procedures are a less-invasive alternative to open and laparoscopic surgery for patients with diseases in the gastrointestinal tract or morbid obesity. It also provides a quicker recovery to minimize the risks of surgical complications.

“Endoluminal surgery is an emerging field and a core focus for our Endoscopy business,” Mike Jones, senior VP and president of endoscopy at Boston Scientific, said in…

Read more
  • 0

DTW #45: Kamen talks 3D organs; Todd Pope returns as CEO; Joe Mulling says Medtech’s time is now

Please lift this jam-packed episode with your legs, not your back.

We’ll hear inspirational words from the legendary Dean Kamen who is shifting his life’s focus into medtech. WellAir’s Todd Pope takes the CEO seat at a new company built to tackle hospital-acquired-infections and COVID Joe Mullings of the Mullings Group explains why now is the best time to be in the Medtech industry.

Chris Newmarker, executive editor of life sciences, delivers a murderers row of #newmarkersnewsmakers with Philips, Medtronic, iRyhthm, Canary Medical and Apollo Endosurgery.

To hear Dean Kamen’s entire interview with Design World’s Paul Heney go here.

Don’t miss a future episode! Subcribe now!

DeviceTalks by MassDevice · Dean Kamen eyeing 3D organs; Todd Pope talks clean air; Joe Mullings says Medtech’s time is now
Read more
  • 0

J&J, Boston Sci vet McKhann to become Apollo Endosurgery’s CEO

Apollo Endosurgery (NSDQ:APEN) announced today that Charles (Chas) McKhann will become its new CEO and join its board of directors.

Current CEO Todd Newton will help facilitate the transition process and agreed to serve as a consultant to the company for up to six months following McKhann’s hire, which becomes effective on March 1, according to a news release.

Newton led the company from the CEO position for more than six years, helping to reposition Apollo’s product portfolio as the company has garnered FDA pre-market approval for the Orbera intragastric balloon, OverStitch Sx endoscopic suturing system and X-Tack endoscopic helix tacking system.

“We are pleased to announce Chas’ appointment, and we want to thank Todd for his excellent stewardship,” Apollo chairman John Barr said in the release. “While Todd’s achievements are many, his leadership during the COVID-19 pandemic has been particularly notable. In the…

Read more
  • 0